Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
CNMD logo CNMD
Upturn stock ratingUpturn stock rating
CNMD logo

CONMED Corporation (CNMD)

Upturn stock ratingUpturn stock rating
$52.08
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/30/2025: CNMD (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

6 Analysts rated it

Moderately tracked stock, growing coverage, gaining market and investor attention.

1 Year Target Price $66.6

1 Year Target Price $66.6

Analysts Price Target For last 52 week
$66.6Target price
Low$45.83
Current$52.08
high$77.23

Analysis of Past Performance

Type Stock
Historic Profit -42.26%
Avg. Invested days 25
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 1.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/30/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 1.61B USD
Price to earnings Ratio 13.69
1Y Target Price 66.6
Price to earnings Ratio 13.69
1Y Target Price 66.6
Volume (30-day avg) 6
Beta 1.24
52 Weeks Range 45.83 - 77.23
Updated Date 06/29/2025
52 Weeks Range 45.83 - 77.23
Updated Date 06/29/2025
Dividends yield (FY) 1.53%
Basic EPS (TTM) 3.81

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Revenue by Geography

Geography revenue - Year on Year

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin 9.02%
Operating Margin (TTM) 7.27%

Management Effectiveness

Return on Assets (TTM) 4.14%
Return on Equity (TTM) 12.96%

Valuation

Trailing PE 13.69
Forward PE 27.03
Enterprise Value 2470804757
Price to Sales(TTM) 1.23
Enterprise Value 2470804757
Price to Sales(TTM) 1.23
Enterprise Value to Revenue 1.88
Enterprise Value to EBITDA 9.75
Shares Outstanding 30939900
Shares Floating 30662953
Shares Outstanding 30939900
Shares Floating 30662953
Percent Insiders 0.58
Percent Institutions 117.51

Analyst Ratings

Rating 3
Target Price 66.6
Buy 2
Strong Buy -
Buy 2
Strong Buy -
Hold 4
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

CONMED Corporation

stock logo

Company Overview

overview logo History and Background

CONMED Corporation was founded in 1970. Initially focused on electrosurgical products, it has grown through acquisitions and organic growth to become a diversified medical technology company.

business area logo Core Business Areas

  • Orthopedic Surgery: Provides a comprehensive suite of products for arthroscopic sports medicine and orthopedic reconstructive procedures.
  • General Surgery: Offers a wide range of products for minimally invasive and open surgical procedures, including advanced energy, smoke evacuation, and surgical visualization products.

leadership logo Leadership and Structure

CONMED is led by its CEO and operates under a board of directors. The company has a functional organizational structure, with departments such as sales, marketing, research and development, and operations.

Top Products and Market Share

overview logo Key Offerings

  • Advanced Surgical: Includes products for advanced energy, such as electrosurgical generators and handpieces. Competitors include Medtronic, Ethicon (Johnson & Johnson).
  • Orthopedics: Encompasses arthroscopic solutions, including surgical tools, implants, and fluid management systems. Competitors include Stryker, Arthrex, and Smith & Nephew.

Market Dynamics

industry overview logo Industry Overview

The medical device industry is experiencing growth due to an aging population, increasing demand for minimally invasive procedures, and technological advancements. It is heavily regulated and subject to intense competition.

Positioning

CONMED holds a strong position in the orthopedic and general surgery markets. Its competitive advantages include a diversified product portfolio and strong brand recognition.

Total Addressable Market (TAM)

The global medical devices market is estimated to be worth hundreds of billions of dollars. CONMED is positioned to capture a portion of this TAM through its focused product offerings and geographic expansion.

Upturn SWOT Analysis

Strengths

  • Diversified product portfolio
  • Established brand reputation
  • Strong sales and distribution network
  • Focus on innovation

Weaknesses

  • Smaller market share compared to larger competitors
  • Dependence on key suppliers
  • Exposure to regulatory risks

Opportunities

  • Expanding into emerging markets
  • Developing new products through research and development
  • Acquiring complementary businesses
  • Capitalizing on the growing demand for minimally invasive procedures

Threats

  • Intense competition from larger players
  • Pricing pressure from healthcare providers
  • Stringent regulatory requirements
  • Product liability claims

Competitors and Market Share

competitor logo Key Competitors

  • MDT
  • JNJ
  • STRY

Competitive Landscape

CONMED competes with larger medical device companies. It differentiates itself through focused product lines and specialized customer service.

Major Acquisitions

Biorez, Inc.

  • Year: 2022
  • Acquisition Price (USD millions): 85
  • Strategic Rationale: Strengthens CONMED's sports medicine portfolio with innovative bio-inductive solutions.

Growth Trajectory and Initiatives

Historical Growth: CONMED has experienced moderate growth through a combination of organic initiatives and strategic acquisitions.

Future Projections: Future growth projections depend on analyst estimates and market conditions.

Recent Initiatives: Recent initiatives include new product launches and geographic expansion into high-growth markets.

Summary

CONMED is a mid-sized medical technology company with a strong position in the orthopedic and general surgery markets. Its diversified product portfolio and focus on innovation are working well, but it faces intense competition from larger players. CONMED needs to capitalize on growth opportunities in emerging markets and continue to invest in research and development to maintain its competitive edge and watch out for regulatory risks.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company Filings
  • Analyst Reports
  • Industry Research Reports
  • CONMED Investor Relations

Disclaimers:

This analysis is for informational purposes only and should not be considered investment advice. Market conditions and company performance are subject to change.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About CONMED Corporation

Exchange NYSE
Headquaters Largo, FL, United States
IPO Launch date 1987-07-23
President, CEO & Director Mr. Patrick J. Beyer
Sector Healthcare
Industry Medical Devices
Full time employees 3900
Full time employees 3900

CONMED Corporation, a medical technology company, develops, manufactures, and sells devices and equipment for surgical procedures in the United States and internationally. The company offers orthopedic surgery products, including BioBrace, TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and Agro Knotless Suture Anchors, which provide clinical solutions to orthopedic surgeons for the augmentation and repair of soft tissue injuries, as well as provides supporting products that enable surgeons to perform minimally invasive sports medicine surgeries. It markets orthopedic surgery products under the Hall, CONMED Linvatec, Concept, and Shutt brands. It also provides battery-powered and autoclavable bone power tool systems for use in orthopedic, arthroscopic, oral/maxillofacial, podiatric, spinal, and cardiothoracic surgeries under Hall surgical brand name. In addition, the company offers general surgery products, including clinical insufflation systems under AirSeal brand; smoke removal devices under Buffalo Filter brand; endomechanical products, such as tissue retrieval bags, trocars, suction irrigation devices, graspers, scissors, and dissectors used in minimally invasive surgeries; and electrosurgical solution comprising monopolar and bipolar generators, argon beam coagulation generators, handpieces, smoke management systems and other accessories. Further, the company provides endoscopic technologies, including therapeutic and diagnostic products for use in gastroenterology procedures, and products for the treatment of diseases of the dilatation, hemostasis, biliary, structure management, and infection prevention; and patient monitoring, including ECG and EEG electrodes, and cardiac defibrillation pads. It markets its products directly to hospitals, surgery centers, and other healthcare institutions, as well as through medical specialty distributors. The company was incorporated in 1970 and is headquartered in Largo, Florida.